Early investigational tubulin inhibitors as novel cancer therapeutics

Reference

• Hadfield JA, Ducki S, Hirst N, et al. Tubulin and microtubules as targets for anticancer drugs. Progress in Cell Cycle Res. 2003;5:309–325.
   PubMedGoogle Scholar
• Meng F, Cai X, Duan J, et al. A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity. Canc Chemoth Pharmaco. 2008;61:953–963.
   PubMed Web of Science ®Google Scholar
• Lu Y, Chen J, Xiao M, et al. An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res. 2012;29:2943–2971.
   PubMed Web of Science ®Google Scholar
• Jordan A, Hadfield JA, Lawrence NJ, et al. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev. 1998;18:259–296.
   PubMed Web of Science ®Google Scholar
• Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol. 1998;10:123–130.
   PubMed Web of Science ®Google Scholar
• Giannakakou P, Sackett D, Fojo TJ. Tubulin/microtubules: still a promising target for new chemotherapeutic agents. Natl Cancer Inst. 2000;92:182–183.
   Google Scholar
• Mangla V, Nepali K, Singh G, et al. Structure activity relationship of arylidene pyrrolo and pyrido [2,1-b] quinazolones as cytotoxic agents: synthesis, SAR studies, biological evaluation and docking studies. Med Chem. 2013;9:642–650.
   PubMed Web of Science ®Google Scholar
• Dumontet C, Jordan MN. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov. 2010;9:790–803.
   PubMed Web of Science ®Google Scholar
• Prota AE, Bargsten K, Zurwerra D, et al. Molecular mechanism of action of microtubule-stabilizing anticancer agents. Science. 2013;339:587–60.
   PubMed Web of Science ®Google Scholar
• Chen J-G, Horwitz SB. Differential mitotic responses to microtubule stabilizing and destabilizing drugs. Cancer Res. 2002;62:1935–1938.
   PubMed Web of Science ®Google Scholar
• Pryor DE, O’Brate A, Bilcer G, et al. The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry. 2002;41:9109–9115.
   PubMed Web of Science ®Google Scholar
• Perez EA. Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther. 2009;8:2086–2095.
   PubMed Web of Science ®Google Scholar
• Yue Q-X, Liu X, Guo D-A. Microtubule-binding natural products for cancer therapy. Planta Med. 2010;76:1037–1043.
   PubMed Web of Science ®Google Scholar
• Kingston DGI. Tubulin-interactive natural products as anticancer agents. J Nat Prod. 2009;72:507–515.
   PubMed Web of Science ®Google Scholar
• Campos SM, Dizon DS. Antimitotic inhibitors. Hematol Oncol Clin N Am. 2012;26:607–628.
   PubMed Web of Science ®Google Scholar
• Mooberry SL, Tien G, Hernandez AH, et al. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents. Cancer Res. 1999;59:653–660.
   PubMed Web of Science ®Google Scholar
• Mulzer J, Ohler E. Microtubule-stabilizing marine metabolite laulimalide and its derivatives: synthetic approaches and antitumor activity. Chem Rev. 2003;103:3753–3786.
   PubMed Web of Science ®Google Scholar
• Pryor DE, O’Brate A, Bilcer G, et al. The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry. 2002;41:9109–9115.
   PubMed Web of Science ®Google Scholar
• Pineda O, Farra`s J, Maccari L, et al. Computational comparison of microtubule-stabilising agents laulimalide and peloruside with taxol and colchicine. Bioorg Med Chem Lett. 2004;14:48.
   Web of Science ®Google Scholar
• Cutts JH, Beer CT, Noble RL. Biological properties of vincaleukoblastine, an alkaloid in Vinca rosea Linn, with reference to its antitumor action. Cancer Res. 1960;20:1023–1031.
   PubMed Web of Science ®Google Scholar
• Wilson L, Meza I. The mechanism of action of colchicine. Colchicine binding properties of sea urchin sperm tail outer doublet tubulin. J Cell Biol. 1973;58:709–719.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya B, Panda D, Gupta S, et al. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Med Res Rev. 2008;28:155–183.
   PubMed Web of Science ®Google Scholar
• Downing KH, Nogales E. New insights into microtubule structure and function from the atomic model of tubulin. Eur Biophys J. 1998;27:431–436.
   PubMed Web of Science ®Google Scholar
• Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev. 1990;9:267–282.
   PubMed Web of Science ®Google Scholar
• Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res. 2004;10:415–427.
   PubMed Web of Science ®Google Scholar
• Siemann DW, Horsman MR. Vascular targeted therapies in oncology. Cell Tissue Res. 2009;335:241–248.
   PubMed Web of Science ®Google Scholar
• Siemann DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat Rev. 2011;37:63–74.
   PubMed Web of Science ®Google Scholar
• McKeage MJ, Baguley BC. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer. 2010;116:1859–1871.
   PubMed Web of Science ®Google Scholar
• Patterson DM, Zweifel M, Middleton MR, et al. Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res. 2012;18:1415–1425.
   PubMed Web of Science ®Google Scholar
• Sessa C, Lorusso P, Tolcher A, et al. Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors. Clin Cancer Res. 2013;19:4832–4842.
   PubMed Web of Science ®Google Scholar
• Mita MM, Spear MA, Yee LK, et al. Phase 1 first-in-human trial of the vascular disrupting agent plinabulin (NPI-2358) in patients with. solid tumors or lymphomas. Clin Cancer Res. 2010;16(23):5892–5899.
   PubMed Web of Science ®Google Scholar
• Millward M, Mainwaring P, Alain Mita A, et al. Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel. Invest New Drugs. 2012;30:1065–1073.
   PubMed Web of Science ®Google Scholar
• Calvert AH, Gonzalez M, Ganguli S, et al. A first-in-human (FIH) dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous BAL101553, a novel microtubule inhibitor, in adult patients with advanced solid tumors. J Clin Oncol. 2013;31:2566.
   Google Scholar
• Oh D-Y, Kim T-M, Han S-W, et al. Phase I study of CKD-516, a novel vascular disrupting agent, in patients with advanced solid tumors. Cancer Res Treat. 2016;48:28–36.
   PubMed Web of Science ®Google Scholar
• Grossmann KF, Colman H, Akerley WA, et al. Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme. J Neuro Oncol. 2012;110:257–264.
   PubMed Web of Science ®Google Scholar
• Burge M, Francesconi B, Kotasek D, et al. Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent. Invest New Drugs. 2013;31:126–135.
   PubMed Web of Science ®Google Scholar
• Clancy MS, Cleary JM, Mani S, et al. Novel tubulin inhibitor ALB 109564(a) in patients with solid tumors: A phase I trial. J Clin Oncol. 2010;28:3119.
   Google Scholar
• Mitchell D, Bergendahl G, Ferguson W, et al. A phase 1 trial of TPI 287 as a single agent and in combination with temozolomide in patients with refractory or recurrent neuroblastoma or medulloblastoma. Pediatr Blood Cancer. 2016;63:39–46.
   PubMed Web of Science ®Google Scholar
• New In Vitro data presented at AACR-NCI-EORTC international conference on molecular targets and cancer therapeutics in San Francisco at International conference on molecular targets and cancer therapeutics in San Francisco; 2007. Available from: http://www.aezsinc.com/en/page.php?p=60&q=249
   Google Scholar
• Mooney CJ, Nagaiah G, Fu P, et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid. 2009;19:233–240.
   PubMed Web of Science ®Google Scholar
• Nowak AK, Brown Chris C, Millward MJ, et al. A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced malignant pleural mesothelioma. Lung Cancer. 2013;81:422–427.
   PubMed Web of Science ®Google Scholar
• Pal S, Azad A, Bhatia S, et al. A phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma. Clin Cancer Res. 2015;21:3420–3427.
   PubMed Web of Science ®Google Scholar
• Von Pawel J, Gorbounova V, Reck M, et al. DISRUPT: A randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane–platinum regimen as first-line therapy for metastatic non-small cell lung cancer. Lung Cancer. 2014;85:224–229.
   PubMed Web of Science ®Google Scholar
• Mauer AM, Cohen EE, Ma PC, et al. A phase II study of ABT-751 in patients with advancednon-small cell lung cancer. J Thor Oncol. 2008;3:631–636.
   PubMed Web of Science ®Google Scholar
• Fox E, Mosse YP, Meany HM, et al. Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: A report from the Children’s Oncology Group (ANBL0621). Pediatr Blood Cancer. 2014;61:990–996.
   PubMed Web of Science ®Google Scholar
• Patel S, Keohan ML, Saif MW, et al. Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. Cancer. 2006;107:2881–2887.
   PubMed Web of Science ®Google Scholar
• D’agostino G, Del Campo J, Mellado B, et al. A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer. Int J Gynecol Cancer. 2006;16:71–76.
   PubMed Web of Science ®Google Scholar
• Pivot X, Koralewski P, Hidalgo JL, et al. A multicenter phase II study of XRP6258 administeredas a 1-h IV. infusion every 3 weeks in taxane-resistantmetastatic breast cancer patients. Ann Oncol. 2008;19:1547–1552.
   Google Scholar
• Diéras V, Limentani S, Romieu G, et al. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann Oncol. 2008;19:1255–1260.
   PubMed Web of Science ®Google Scholar
• Beer M, Lenaz L, Amadori D, et al. Phase II study of ortataxel in taxane-resistant breast cancer and Ortataxel Study Group. J Clin Oncol. 2008;26:1066.
   PubMed Web of Science ®Google Scholar
• Mekhail T, Serwatowski P, Dudek A, et al. A phase II study of intravenous (IV) milataxel for the treatment of non-small cell lung cancer (NSCLC) refractory to platinum- based therapy. Proc Am Soc Clini Oncol. 2006;24:7098–7005.
   Google Scholar
• DJ-927 as second-line therapy in treating patients with progressive locally advanced or metastatic colorectal adenocarcinoma. Available from: https://clinicaltrials.gov/ct2/show/NCT00080834?term=tesetaxel&rank=14&submit_fld_opt
   Google Scholar
• Camps C, Felip E, Sanchez JM, et al. Phase II trial of the novel taxane. BMS-184476 as second-line in nonsmall-cell lung cancer. Ann Oncol. 2005;16:4597–4601.
   Google Scholar
• Homsi J, Bedikian AY, Kim KB, et al. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients. Melanoma Res. 2009;19:238–242.
   PubMed Web of Science ®Google Scholar
• Dipetrillo T, Suntharalingam M, Ng T, et al. Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial. Am J Clin Oncol. 2012;35:64–67.
   PubMed Web of Science ®Google Scholar
• Jeyapalan SA, Goldmann M, Donahue J, et al. A phase II study of paclitaxel poliglumex (PPX), temozolamide (TMZ), and radiation (RT) for newly diagnosed high-grade Gliomas. J Clin Oncol. 2011;29:(suppl; abstr 2036).
   Web of Science ®Google Scholar
• Antonarakis ES, Heath EI, Posadas EM, et al. A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2013;71:883–892.
   PubMed Web of Science ®Google Scholar
• Aeterna zentaris presents phase 1 results for AEZS-112 in patients with advanced cancer and lymphoma at AACR annual meeting in Denver, 2009. Available from: http://www.prnewswire.com/news-releases/aeterna-zentaris.html
   Google Scholar
• Young SL, Chaplin DJ. Combretastatin A4 phosphate: background and current clinical status. Expert Opin Investig Drugs. 2004;13:1171–1182.
   PubMed Web of Science ®Google Scholar
• Tozer GM, Kanthou C, Parkins CS, et al. The biology of the combretastatins as tumour vascular targeting agents. Int J of Exper Pathol. 2002;83:21–38.
   PubMed Web of Science ®Google Scholar
• Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4 phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing. Anticancer Drugs. 1993;4:3–17.
   Web of Science ®Google Scholar
• Vincent L, Kermani P, Young LM, et al. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest. 2005;115:2992–2996.
   PubMed Web of Science ®Google Scholar
• Nathan PD, Judson I, Padhani A, et al. A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. J Clin Oncol. 2008;26:3550–3564.
   Web of Science ®Google Scholar
• Nathan P, Zweifel M, Padhani AR, et al. Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res. 2012;18:3428–3439.
   PubMed Web of Science ®Google Scholar
• Salmon HW, Siemann DW. Effect of the second-generation vascular disrupting Agent OXi4503 on tumor vascularity. Clin Cancer Res. 2006;12:4090–4094.
   PubMed Web of Science ®Google Scholar
• Cumming J, Zweifel M, Smith N, et al. Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial. Br J Cancer. 2012;106:1766–1771.
   PubMed Web of Science ®Google Scholar
• Sheng Y, Hua J, Pinney KG, et al. Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis. Int J Cancer. 2004;111:604–610.
   PubMed Web of Science ®Google Scholar
• Dalal S, Burchill SA. Preclinical evaluation of vascular-disrupting agents in Ewing’s sarcoma family of tumours. Eur J Cancer. 2009;45:713–722.
   PubMed Web of Science ®Google Scholar
• Folkes LK, Christlieb M, Madej E, et al. Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals. Chem Res Toxicol. 2007;20:1885–1894.
   PubMed Web of Science ®Google Scholar
• Flynn BL, Gill GS, Grobelny DW, et al. Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties. J Med Chem. 2011;54:6014–6027.
   PubMed Web of Science ®Google Scholar
• Rischin D, Bibby DC, Chong G, et al. Clinical pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation. Clin Cancer Res. 2011;17:5152–5160.
   PubMed Web of Science ®Google Scholar
• Kremmidiotis G, Leske AF, Lavranos TC, et al. BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy. Mol Cancer Ther. 2010;9:1562–1573.
   PubMed Web of Science ®Google Scholar
• Rischin D, Bibby DC, Chong G, et al. Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation. Clin Cancer Res. 2011;17:5152–5160.
   PubMed Web of Science ®Google Scholar
• Lee H-Y, Chang C-Y, Lai M-J, et al. Antimitotic and antivascular activity of heteroaroyl-2-hydroxy-3,4,5-trimethoxybenzenes. Bio Med Chem. 2015;23:4230–4236.
   PubMed Web of Science ®Google Scholar
• Kuo C-C, Hsieh H-P, Pan W-Y, et al. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res. 2004;64:4621–4628.
   PubMed Web of Science ®Google Scholar
• Chen CP, Hu CB, Yeh KC, et al. Antiangiogenic activities and cisplatin-combined antitumor activities of BPR0L075. Anticancer Res. 2010;30:2813–22.
   PubMed Web of Science ®Google Scholar
• Liu L, Beck H, Wang X, et al. Tubulin-destabilizing agent BPR0L075 induces vascular-disruptionin human breast cancer mammary fat pad xenografts. PLoS One. 2012;7:e43314.
   Web of Science ®Google Scholar
• Kim TJ, Ravoori M, Landen CN, et al. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res. 2007;67:9337–9345.
   PubMed Web of Science ®Google Scholar
• Morinaga Y, Suga Y, Ehara S, et al. Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo. Cancer Sci. 2003;94:200–204.
   PubMed Web of Science ®Google Scholar
• Demers B, Vrignaud P, Bissery M, et al. In vivo synergy combining oxaliplatin with AVE8062, a vascular-disrupting agent. J Clin Oncol. 2006;24:13074.
   Google Scholar
• Hori K, Saito S, Sato Y, et al. Differential relationship between changes in tumour size and microcirculatory functions induced by therapy with an antivascular drug and with cytotoxic drugs - implications for the evaluation of therapeutic efficacy of AC7700 (AVE8062). Eur J Cancer. 2003;39:1957–1966.
   PubMed Web of Science ®Google Scholar
• Hori K, Saito S, Kubota K, et al. A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br J Cancer. 2002;86:1604–1614.
   PubMed Web of Science ®Google Scholar
• Kim TJ, Ravoori M, Landen CN, et al. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res. 2007;67:9337–9345.
   PubMed Web of Science ®Google Scholar
• Clémenson C, Jouannot E, Merino-Trigo A, et al. The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and necksquamous cell carcinoma xenograft models. Invest New Drugs. 2013;31:273–284.
   PubMed Web of Science ®Google Scholar
• Eskens F, Tresca P, Tosi D, et al. A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours. Br J Cancer. 2014;110:2170–2177.
   PubMed Web of Science ®Google Scholar
• Bahleda R, Sessa C, Del CG, et al. Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors. Invest New Drugs. 2014;32:1188–1196.
   PubMed Web of Science ®Google Scholar
• Yee KWL, Hagey A, Verstovsek S, et al. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2005;11:6615–6618.
   PubMed Web of Science ®Google Scholar
• Ji Y-T, Liu Y-N, Liu Z-P. Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments. Curr Med Chem. 2015;22:1348–1360.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Mauer A, Smakal M, et al. Phase I/II study of pemetrexed with or without ABT-751in advanced or metastatic non–small-cell lung cancer. J Clin Oncol. 2011;29:1075–1082.
   PubMed Web of Science ®Google Scholar
• Iwamoto Y, Nishio K, Fukumoto H, et al. Preferential binding of E7010 to murine β3-tubulin and decreased β3-tubulin in E7010-resistant cell lines. Jpn J Cancer Res. 1998;89:954–962.
   PubMedGoogle Scholar
• Li Q, Sham HL. Discovery and development of antimitotic agents that inhibit tubulin polymerisation for the treatment of cancer. Expert Opin Ther Patents. 2002;12:1663–1673.
   Web of Science ®Google Scholar
• Yoshimatsu K, Yamaguchi A, Yoshino H, et al. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res. 1997;57:3208–3213.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Noda K, Yoshimura A, et al. Phase I study of E7010. Cancer Chemother Pharmacol. 1998;42:127–134.
   PubMed Web of Science ®Google Scholar
• Meany H, Fox E, Hagey AE, et al. In vitro cytotoxicity of ABT-751, a novel tubulin inhibitor, in pediatric solid tumor cell lines [abstract #4351]. Proc Am Assoc Cancer Res. 2006;47:1021–1032.
   Google Scholar
• Yoshimatsu K, Yamaguchi A, Yoshino H, et al. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res. 1997;57:3208–3213.
   PubMed Web of Science ®Google Scholar
• Koyanagi N, Nagasu T, Fujita F, et al. In vivotumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Cancer Res. 1994;54:1702–1706.
   PubMed Web of Science ®Google Scholar
• Jorgensen TJ, Tian H, Joseph IB, et al. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth. Cancer Chemother Pharmacol. 2007;59:725–732.
   PubMed Web of Science ®Google Scholar
• Hande KR, Hagey A, Berlin J, et al. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res. 2006;12:2834–2840.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Mauer A, Smakal M. Phase I/II study of pemetrexed with or without ABT-751in advanced or metastatic non–small-cell lung cancer. J Clin Oncol. 2011;29:1075–1082.
   PubMed Web of Science ®Google Scholar
• Yamazaki Y, Tanaka K, Nicholson B, et al. Synthesis and structure–activity relationship study of antimicrotubule agents phenylahistin derivatives with a didehydropiperazine-2,5-dione structure. J Med Chem. 2012;55:1056−71.
   PubMed Web of Science ®Google Scholar
• Lockman PR, Mittapalli RK, Taskar KS, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res. 2010;16:5664–5678.
   PubMed Web of Science ®Google Scholar
• Nicholson B, Lloyd GK, Miller BR, et al. NPI-2358 is a tubulin depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006;17:25–31.
   PubMed Web of Science ®Google Scholar
• Bertelsen LB, Shen YY, Nielsen T, et al. .Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation. Int J Radiat Biol. 2011;87:1126–1134.
   PubMed Web of Science ®Google Scholar
• Lloyd GK, Nicholson B, Neuteboom STC, et al. NPI- 2358: a new vascular/tubulin modifying agent greatly potentiates standard chemotherapy in xenograft models. EORTC-NCIAACR Molecular Targets and Therapeutics Meeting; 2003; Boston, MA.
   Google Scholar
• Kolb EA, Gorlick R, Keir T, et al. Initial testing (Stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2015;62:1106–1109.
   PubMed Web of Science ®Google Scholar
• Prota AE, Danel F, Bachmann F, et al. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization. J Mol Biol. 2014;426:1848–1860.
   PubMed Web of Science ®Google Scholar
• Kolb EA, Gorlick R, Keir ST, et al. Initial testing (Stage 1) of BAL101553, a novel tubulin binding agent,by the pediatric preclinical testing program. Pediatr Blood Cancer. 2015;62:1106–1109.
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testingprogram: description of models and early testing results. Pediatr Blood Cancer. 2007;49:928–940.
   PubMed Web of Science ®Google Scholar
• Lee J, Kim SJ, Choi H, et al. Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors. J Med Chem. 2010;53:6337–6354.
   PubMed Web of Science ®Google Scholar
• Kasibhatla S, Baichwal V, Cai SX, et al. MPC-6827: a small-molecule inhibitor of microtubule formationthat is not a substrate for multidrug resistance pumps. Cancer Res. 2007;67:5865–5871.
   PubMed Web of Science ®Google Scholar
• Chen X, Yang C, Xu Y, et al. The microtubule depolymerizing agent CYT997 effectively kills acute myeloid leukemia cells via activation of caspases and inhibition of PI3K/Akt/mTOR pathway proteins. Exp Ther Med. 2013;6:299–304.
   PubMed Web of Science ®Google Scholar
• Zhu JJ, Kesari S, Recht L. Phase II study of verubulin (Azixa, MPC-6827) with radiation therapy and temozolomide in newly diagnosed glioblastoma multiforme patients: incomplete report on safety, tolerability and responses. Neurology. 2015;84(14 Supplement):P3.125.
   Google Scholar
• Milanowskia DJ, Keilmana J, Guob C, et al. Isolation and identification of five impurities of ALB 109564(a) drug substance. J Pharma Biomed Anal. 2011;55:366–372.
   PubMed Web of Science ®Google Scholar
• Clancy MS, Cleary JM, Mani S. Novel tubulin inhibitor ALB 109564(a) in patients with solid tumors: A phase I trial. J Clin Oncol. 2010;28:531–545.
   PubMed Web of Science ®Google Scholar
• Wolf MA, Johnson RK, Xie D, et al. Abstract C232: ALB-109564, a novel tubulin inhibitor with improved efficacy over vinorelbine, is better tolerated when dosed iv versus ip, leading to improved activity in human tumor xenograft studies. Mol Cancer Ther. 2009;8:1502–1521.
   Google Scholar
• Miyazaki K, Kobayashi M, Natsume T, et al. Synthesis and antitumor activity of novel dolastatin 10 analogs. Chem Pharm Bull. 1995;43:1706–1718.
   PubMed Web of Science ®Google Scholar
• Natsume T, Watanabe J, Tamaoki S, et al. Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin. Jpn J Cancer Res. 2000;91:737–747.
   PubMedGoogle Scholar
• Watanabe J, Natsume T, Fujio N, et al. Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent. Apoptosis. 2000;5:345–353.
   PubMed Web of Science ®Google Scholar
• Hashiguchi N, Kubota T, Koh J, et al. TZT-1027 elucidates antitumor activity through directcytotoxicity and selective blockage of blood supply. Anticancer Res. 2004;24:2201–2208.
   PubMed Web of Science ®Google Scholar
• Natsume T, Watanabe J, Koh Y, et al. Antitumor activity of TZT-1027 (Soblidotin)against vascular endothelial growth factor-secreting human lung cancer in vivo. Cancer Sci. 2003;94:826–833.
   PubMed Web of Science ®Google Scholar
• Otani M, Natsume T, Watanabe JI, et al. TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. Jpn J Cancer Res. 2000;91:837–844.
   PubMedGoogle Scholar
• Watanabe J, Minami M, Kobayashi M. Antitumor activityof TZT-1027 (Soblidotin). Anticancer Res. 2006;26:1973–1981.
   PubMed Web of Science ®Google Scholar
• Watanabe J, Natsume T, Fujio N, et al. Induction of apoptosis in human cancer cells by TZT-1027,an antimicrotubule agent. Apoptosis. 2000;5:345–353.
   PubMed Web of Science ®Google Scholar
• Watanabe J, Natsume T, Kobayashi M. Antivascular effectsof TZT-1027 (Soblidotin) on murine colon 26 adenocarcinoma. Cancer Sci. 2006;97:1410–1416.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Natsume T, Tamaoki S, et al. Antitumor activity of TZT-1027, a novel doiastatin 10 derivative. Jpn J Cancer Res. 1997;88:316–327.
   PubMedGoogle Scholar
• Ogawa T, Mimura Y, Isowa K, et al. An antimicrotubule agent, TZT-1027, does not induce neuropathologic alterations which are detected after administration of vincristineor paclitaxel in animal models. Toxicol Lett. 2001;121:97–106.
   PubMed Web of Science ®Google Scholar
• Goldsmith MF. Researchers look forward to sea granting gifts. Jama. 1996;275:975–977.
   PubMed Web of Science ®Google Scholar
• Wagner MM, Paul DC, Shih C, et al. In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines. Cancer Chemother Pharmacol. 1999;43:115–125.
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Serpico D, Rodon J, et al. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. Mol Cancer Ther. 2012;11:2062–2071.
   PubMed Web of Science ®Google Scholar
• Emerson DL, Bell C, Jones ME, et al. Oral bioavailabity and antitumor activity of TPI 287 a new taxane analog with greater activity than paclitaxel against tumor cells with demonstrated mutant tubulin. Cancer Res. 2006;66:116–117.
   Google Scholar
• Fitzgerald P, Emerson DL, Qian Y, et al. TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells. Mol Cancer Ther. 2012;11:1959–1967.
   PubMed Web of Science ®Google Scholar
• Jones M, Bell C, Brown E. TPI 287 crosses the blood brain barrier and contributes to antitumor activity in the U251 glioblastoma intracranial tumor model in nude mice. Cancer Res. 2007;67:1441–1445.
   Google Scholar
• Bouchard H, Semiond D, Risse ML, et al. Novel taxanes: cabazitaxel case study. In: Fischer J, Ganellin CR, Rotella DP, editors. Analogue-based drug discovery III. Vol. 13. 1st ed. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA; 2013; p. 319–341.
   Google Scholar
• Abidi A. Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects. J Pharmacol Pharmacother. 2013;4:230–237.
   PubMedGoogle Scholar
• Bissery MC, Bouchard H, Riou J, et al. Preclinical evaluation of TXD258, a new taxoid. Cabazitaxel displayed remarkable cytotoxic potential in docetaxel sensitive cell lines P388 (lymphoblastic leukemia), HL60 (promyelocytic leukemia), KB (cervical ademocarcinoma) and Calc18 (breast carcinoma). Proc Am Assoc Cancer Res. 2000;41:214–223.
   Google Scholar
• Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009;15:723–730.
   PubMed Web of Science ®Google Scholar
• De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration resistant prostate cancer progressing after docetaxel treatment: a randomised open label trial. Lancet. 2010;376:1147–1154.
   PubMed Web of Science ®Google Scholar
• Rixea O, Puzanovb I, LoRussoc PM, et al. Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies. Anti-Cancer Drugs. 2015;26:785–792.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Skoneczna IA, Castellano D, et al. Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB). Oncol. 2013;85:208–215.
   Google Scholar
• Yamamoto N, Boku N, Minami H, et al. Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours.). Cancer Chemother Pharmacol. 2009;65:129–136.
   PubMed Web of Science ®Google Scholar
• Sessa C, Cuvier C, Caldiera S, et al. Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors. Ann Oncol. 2002;13:1140–1150.
   PubMed Web of Science ®Google Scholar
• Dieras V, Viens P, Veyret C, et al. Larotaxel (L) in combination with trastuzumab in patients with HER2 + metastatic breast cancer (MBC): interim analysis of an open phase II label study. J Clin Oncol. 2008;26:1070–1083.
   Google Scholar
• Sternberg CN, Skoneczna IA, Castellano D, et al. Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB). Oncology. 2013;85:208–215.
   PubMed Web of Science ®Google Scholar
• Polizzi D, Pratesi G, Monestiroli S, et al. Oral efficacy and bioavailability of a novel taxane. Clin Cancer Res. 2000;6:2070–2074.
   PubMed Web of Science ®Google Scholar
• Polizzi D, Pratesi G, Monestiroli S, et al. Oral efficacy and bioavailability of a novel taxane. Clin Cancer Res. 2000;6:2070–2074. [PubMed: 10815934].
   PubMed Web of Science ®Google Scholar
• Nicoletti MI, Colombo T, Rossi C, et al. IDN5109, a taxane with oral bioavailability and potent antitumor activity. Cancer Res. 2000;60:842–846.
   PubMed Web of Science ®Google Scholar
• Tonkin K, Herbert H, Lathia C, et al. A Phase I and pharmacokinetic study of a novel oral taxane BAY 59–8862 in solid tumors. Proc Am Soc Clin Oncol. 2003;22:Abstract 965.
   Google Scholar
• Sampath D, Discafani CM, Loganzo F, et al. MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo. Mol Cancer Ther. 2003;2:873–884.
   PubMed Web of Science ®Google Scholar
• Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport,and cell death. J Clin Oncol. 1999;17:1061–1070.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Shapiro M, Carducci K, et al. Phase I trial of apotent novel taxane, TL00139 (MAC-321), in patients with advanced malignant solid tumors. Proc Am Soc Clini Oncol. 2003;22:132–145.
   Google Scholar
• Lockhart AC, Bukowski R, Rothenberg ML, et al. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors. Cancer Chemother Pharmacol. 2007;60:203–209.
   PubMed Web of Science ®Google Scholar
• Bourbouloux E, Campone M, Vermorken JB, et al. Phase I study of intravenous (IV) milataxel in adult patients with advanced malig-nant tumors. J Clin Oncol. 2006;24:2037–2046.
   Google Scholar
• Beeram M, Papadopoulos K, Patnaik A, et al. Phase I dose-ranging, pharmacokinetic (PK) study of tesetaxel, a novel orally active tubulin-binding. J Clin Oncol. 2010;28:3075–3082.
   Google Scholar
• Shionoya M, Jimbo T, Kitagawa M, et al. DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Sci. 2003;94:459–466.
   PubMed Web of Science ®Google Scholar
• Flores JP, Saif MW. Novel oral taxane therapies: recent phase I results. Clin Investig. 2013;3:333–341.
   Google Scholar
• Altstadt TJ, Fairchild CR, Golik J, et al. Synthesis and antitumor activity of novel C-7 paclitaxel ethers: discovery of BMS-184476. J Med Chem. 2001;44:4577–4583.
   PubMed Web of Science ®Google Scholar
• Bradley MO, Webb NL, Anthony FH, et al. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin Cancer Res. 2001;7:3229–3238.
   PubMed Web of Science ®Google Scholar
• Bradley MO, Swindell CS, Anthony FH, et al. Tumor targeting by conjugation of DHA to paclitaxel. J Control Release. 2001;74:233–236.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Donehower RC, Carducci MK, et al. Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin Cancer Res. 2003;9:3589–3597.
   PubMed Web of Science ®Google Scholar
• Fracasso PM, Picus J, Wildi JD, et al. Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin®, in resistant solid tumor malignancies. Cancer Chemother Pharmacol. 2009;63:451–458.
   PubMed Web of Science ®Google Scholar
• Singer J. Paclitaxel poliglumex (XYOTAX™, CT-2103): A macromolecular taxane. J Control Release. 2005;109:120–126.
   PubMed Web of Science ®Google Scholar
• Li C, Ke S, Wu Q, et al. Tumor irradiation enhances the tumor-specific distribution of poly (l-glutamic acid)-conjugated paclitaxel and its antitumor efficacy. Clin Cancer Res. 2000;6:2829–2834.
   PubMed Web of Science ®Google Scholar
• Fallah-Tafti A, Foroumadi A, Tiwari R, et al. Thiazolyl N-benzyl-substituted acetamide derivatives: synthesis, Src kinase inhibitory and anticancer activities. Eur J Med Chem. 2011;46:4853–4858.
   PubMed Web of Science ®Google Scholar
• Hangauer D, Gelman I, Dyster L, et al. Potent and selective in vitro and in vivo inhibition of tumor proliferation by KXO1, a novel non-ATP competitive Src inhibitor. Proc Am Assoc Cancer Res. 2007;67:3245–3254.
   Google Scholar
• Bu Y, Gao L, Smolinski M, et al. KX01 (KX2-391), a Src family kinase inhibitor targeting the peptide-binding domain, suppresses oncogenic proliferation in vitro and in vivo. Cancer Res. 2008;68:4983.
   PubMed Web of Science ®Google Scholar
• Faris JE, Arnott J, Zheng H, et al. A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. Invest New Drugs. 2012;30:1614–1620.
   PubMed Web of Science ®Google Scholar